Study Finds Early Potential in GSK Leukemia Drug

Scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL)— the most common form of leukemia in babies.

Most patients don’t respond well to standard leukemia treatments and often the cancer comes back. The disease is caused when a gene called MLL gets fused to another gene. This disrupts the normal function of MLL by creating a new “fusion protein” that behaves wrongly, switching on genes that drive the development of leukemia.

Using I-BET151 to treat leukemia in mice and human cancer cells in a lab, the researchers found that the chemical could halt the disease, paving the way for more research to be done in first-stage, or so-called Phase I, human trials. Read more…


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: